A Phase II Pilot Trial to Evaluate CoBaT-Y017 Safety and Efficacy against Uncomplicated Falciparum Malaria versus Artemether-Lumefantrine in Benin Subjects

Table 5

Incidence of adverse events in both treatment arms.

(Adverse events (n (%) E)	CoBaT-Y017: n = 13	AL: n = 12
Increased appetite	2 (15.4 (%) 4)	(0 (%) 0)
Headache	4 (30.8 (%) 6)	8 (66.7 (%) 11)
Fatigue	0 (0 (%) 0)	5 (41.7 (%) 8)
Drowsiness	2 (15.4 (%) 3)	1 (8.3 (%) 1)
Vomiting	2 (15.4 (%) 2)	0 (0 (%) 0)
Nausea	2 (15.4 (%) 2)	0 (0 (%) 0)
Insomnia	0 (0 (%) 0)	1 (8.3 (%) 2)
Abdominal pain	0 (0 (%) 0)	1 (8.3 (%) 2)
Stiffness	0 (0 (%) 0)	2 (16.7 (%) 2)
Rash	0 (0 (%) 0)	1 (8.3 (%) 3)
No adverse events	5 (38.5%)	0 (0 (%) 0)

n: number; %: percent; E: episode.